US FDA Approves Roche’s Tecentriq as Adjuvant Treatment for Early NSCLC
The US Food and Drug Administration (FDA) has approved Roche’s Tecentriq or atezolizumab as adjuvant treatment for patients with Stage
Everything about lung cancer is here.
Everything about lung cancer is here.
The US Food and Drug Administration (FDA) has approved Roche’s Tecentriq or atezolizumab as adjuvant treatment for patients with Stage